Author response: Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease
- 19 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 94 (20), 899
- https://doi.org/10.1212/wnl.0000000000009448
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- β-adrenoreceptors and the risk of Parkinson's diseaseThe Lancet Neurology, 2020
- Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson diseaseNeurology, 2019
- Chronic Use of β-Blockers and the Risk of Parkinson’s DiseaseClinical Drug Investigation, 2019
- β2‐adrenoreceptor medications and risk of Parkinson diseaseAnnals of Neurology, 2018
- β2‐adrenoceptor agonists and antagonists and risk of Parkinson's diseaseMovement Disorders, 2018
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s diseaseScience, 2017